Concepts (269)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Exercise | 54 | 2024 | 970 | 7.050 |
Why?
|
| Insulin | 27 | 2023 | 696 | 3.860 |
Why?
|
| Energy Metabolism | 25 | 2019 | 400 | 3.610 |
Why?
|
| Metformin | 10 | 2022 | 77 | 3.450 |
Why?
|
| Blood Glucose | 26 | 2023 | 502 | 2.680 |
Why?
|
| Energy Intake | 10 | 2019 | 173 | 2.360 |
Why?
|
| Insulin Resistance | 16 | 2024 | 415 | 2.190 |
Why?
|
| Hypoglycemic Agents | 7 | 2022 | 225 | 1.810 |
Why?
|
| Diabetes Mellitus, Type 2 | 12 | 2022 | 733 | 1.530 |
Why?
|
| Obesity | 13 | 2024 | 1277 | 1.320 |
Why?
|
| Glucose Intolerance | 6 | 2014 | 90 | 1.280 |
Why?
|
| Overweight | 7 | 2024 | 254 | 1.210 |
Why?
|
| Oxygen Consumption | 12 | 2013 | 213 | 1.130 |
Why?
|
| Altitude | 5 | 2017 | 15 | 0.960 |
Why?
|
| Diabetes, Gestational | 11 | 2023 | 142 | 0.950 |
Why?
|
| Hormones | 4 | 2010 | 62 | 0.910 |
Why?
|
| Hyperglycemia | 2 | 2018 | 109 | 0.890 |
Why?
|
| Adult | 54 | 2024 | 17511 | 0.890 |
Why?
|
| Carbohydrate Metabolism | 7 | 2013 | 49 | 0.890 |
Why?
|
| Prediabetic State | 2 | 2017 | 54 | 0.820 |
Why?
|
| Risk Reduction Behavior | 4 | 2020 | 122 | 0.810 |
Why?
|
| Healthy Lifestyle | 2 | 2020 | 28 | 0.750 |
Why?
|
| Weight Loss | 3 | 2014 | 275 | 0.750 |
Why?
|
| Heart Rate | 6 | 2017 | 334 | 0.750 |
Why?
|
| Humans | 79 | 2024 | 65645 | 0.710 |
Why?
|
| Female | 56 | 2024 | 34309 | 0.690 |
Why?
|
| Lipid Metabolism | 5 | 2013 | 225 | 0.680 |
Why?
|
| Military Personnel | 1 | 2022 | 110 | 0.670 |
Why?
|
| Motor Activity | 5 | 2011 | 346 | 0.670 |
Why?
|
| Physical Fitness | 5 | 2022 | 93 | 0.670 |
Why?
|
| Appetite Regulation | 2 | 2012 | 8 | 0.650 |
Why?
|
| Appetite | 2 | 2010 | 16 | 0.630 |
Why?
|
| Postmenopause | 2 | 2020 | 239 | 0.610 |
Why?
|
| Dietary Carbohydrates | 3 | 2008 | 62 | 0.610 |
Why?
|
| Exercise Therapy | 2 | 2020 | 102 | 0.580 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 59 | 0.580 |
Why?
|
| Nutritional Status | 1 | 2019 | 101 | 0.570 |
Why?
|
| Running | 2 | 2017 | 83 | 0.570 |
Why?
|
| Weight Gain | 4 | 2017 | 165 | 0.550 |
Why?
|
| Male | 36 | 2022 | 31292 | 0.540 |
Why?
|
| Cancer Survivors | 1 | 2020 | 130 | 0.540 |
Why?
|
| Glucose Tolerance Test | 8 | 2020 | 97 | 0.520 |
Why?
|
| Heart Diseases | 1 | 2019 | 223 | 0.510 |
Why?
|
| Fitness Trackers | 1 | 2017 | 20 | 0.510 |
Why?
|
| Cross-Over Studies | 6 | 2018 | 163 | 0.500 |
Why?
|
| Exercise Test | 7 | 2022 | 257 | 0.500 |
Why?
|
| Leptin | 4 | 2012 | 89 | 0.490 |
Why?
|
| Metabolic Syndrome | 4 | 2024 | 146 | 0.490 |
Why?
|
| Liver | 2 | 2019 | 874 | 0.470 |
Why?
|
| Young Adult | 17 | 2023 | 4855 | 0.460 |
Why?
|
| Body Composition | 8 | 2022 | 155 | 0.460 |
Why?
|
| Fasting | 3 | 2015 | 52 | 0.460 |
Why?
|
| Postpartum Period | 4 | 2024 | 189 | 0.450 |
Why?
|
| Glucose Clamp Technique | 4 | 2011 | 57 | 0.440 |
Why?
|
| Ghrelin | 3 | 2012 | 18 | 0.440 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 555 | 0.430 |
Why?
|
| Cardiovascular Diseases | 4 | 2024 | 872 | 0.430 |
Why?
|
| Social Media | 1 | 2017 | 129 | 0.430 |
Why?
|
| Middle Aged | 18 | 2020 | 18439 | 0.410 |
Why?
|
| Glycogen | 4 | 2013 | 40 | 0.410 |
Why?
|
| Estrogens | 3 | 2006 | 115 | 0.410 |
Why?
|
| Risk Factors | 14 | 2024 | 5466 | 0.400 |
Why?
|
| Health Behavior | 7 | 2018 | 485 | 0.400 |
Why?
|
| Workplace | 1 | 2014 | 177 | 0.380 |
Why?
|
| Progesterone | 3 | 2003 | 165 | 0.360 |
Why?
|
| Eating | 3 | 2010 | 140 | 0.350 |
Why?
|
| Birth Weight | 3 | 2017 | 83 | 0.350 |
Why?
|
| Pregnancy Complications | 4 | 2020 | 389 | 0.340 |
Why?
|
| Pregnancy | 18 | 2024 | 2393 | 0.340 |
Why?
|
| Glucose | 6 | 2023 | 478 | 0.330 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 1233 | 0.330 |
Why?
|
| Adiposity | 2 | 2013 | 89 | 0.320 |
Why?
|
| Bicycling | 1 | 2010 | 20 | 0.310 |
Why?
|
| Adolescent | 16 | 2022 | 6350 | 0.300 |
Why?
|
| Body Mass Index | 8 | 2020 | 900 | 0.300 |
Why?
|
| Area Under Curve | 5 | 2015 | 149 | 0.300 |
Why?
|
| Homeostasis | 3 | 2013 | 383 | 0.290 |
Why?
|
| Double-Blind Method | 6 | 2013 | 745 | 0.290 |
Why?
|
| Life Style | 6 | 2024 | 324 | 0.290 |
Why?
|
| Diet | 3 | 2015 | 536 | 0.290 |
Why?
|
| Monitoring, Physiologic | 1 | 2009 | 169 | 0.280 |
Why?
|
| Metabolism | 1 | 2008 | 12 | 0.280 |
Why?
|
| Prenatal Care | 3 | 2015 | 173 | 0.270 |
Why?
|
| Sex Characteristics | 1 | 2010 | 214 | 0.270 |
Why?
|
| Adaptation, Physiological | 2 | 2008 | 132 | 0.270 |
Why?
|
| Oxidation-Reduction | 5 | 2010 | 328 | 0.270 |
Why?
|
| Food | 1 | 2008 | 76 | 0.270 |
Why?
|
| Walking | 3 | 2018 | 247 | 0.260 |
Why?
|
| Aging | 2 | 2023 | 775 | 0.260 |
Why?
|
| Postprandial Period | 2 | 2018 | 20 | 0.250 |
Why?
|
| C-Reactive Protein | 3 | 2015 | 169 | 0.250 |
Why?
|
| Reproducibility of Results | 2 | 2009 | 1715 | 0.250 |
Why?
|
| Massachusetts | 8 | 2024 | 2154 | 0.240 |
Why?
|
| Cardiovascular System | 1 | 2006 | 41 | 0.240 |
Why?
|
| Respiration | 1 | 2006 | 97 | 0.230 |
Why?
|
| Time Factors | 8 | 2011 | 3777 | 0.230 |
Why?
|
| Rest | 2 | 2002 | 45 | 0.230 |
Why?
|
| Fetal Macrosomia | 2 | 2015 | 13 | 0.230 |
Why?
|
| Androgens | 1 | 2005 | 67 | 0.220 |
Why?
|
| Testosterone | 1 | 2005 | 128 | 0.210 |
Why?
|
| Hypertension, Pregnancy-Induced | 2 | 2016 | 53 | 0.210 |
Why?
|
| Postnatal Care | 2 | 2015 | 45 | 0.210 |
Why?
|
| Biomarkers | 5 | 2024 | 1487 | 0.210 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2003 | 83 | 0.190 |
Why?
|
| Muscle, Skeletal | 2 | 2010 | 788 | 0.190 |
Why?
|
| Feeding Behavior | 2 | 2015 | 266 | 0.190 |
Why?
|
| Body Weight | 5 | 2019 | 377 | 0.180 |
Why?
|
| Calorimetry, Indirect | 2 | 2013 | 32 | 0.170 |
Why?
|
| Pregnancy Outcome | 3 | 2018 | 202 | 0.170 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2020 | 13 | 0.170 |
Why?
|
| Anaerobic Threshold | 2 | 2013 | 12 | 0.170 |
Why?
|
| Firefighters | 1 | 2020 | 1 | 0.160 |
Why?
|
| Vascular Stiffness | 1 | 2020 | 17 | 0.160 |
Why?
|
| Occupational Stress | 1 | 2020 | 22 | 0.160 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2011 | 83 | 0.160 |
Why?
|
| Fatigue | 1 | 2020 | 114 | 0.150 |
Why?
|
| Protective Factors | 1 | 2019 | 33 | 0.150 |
Why?
|
| Lipids | 2 | 2015 | 330 | 0.150 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2019 | 6 | 0.150 |
Why?
|
| Rodentia | 1 | 2019 | 20 | 0.150 |
Why?
|
| Exercise Tolerance | 1 | 2019 | 85 | 0.140 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2013 | 52 | 0.140 |
Why?
|
| Physical Conditioning, Animal | 1 | 2019 | 47 | 0.140 |
Why?
|
| Meals | 1 | 2018 | 27 | 0.140 |
Why?
|
| Monitoring, Ambulatory | 2 | 2009 | 56 | 0.140 |
Why?
|
| Absorptiometry, Photon | 2 | 2008 | 76 | 0.130 |
Why?
|
| Random Allocation | 1 | 2017 | 200 | 0.120 |
Why?
|
| Pulmonary Gas Exchange | 2 | 2008 | 43 | 0.120 |
Why?
|
| Cesarean Section | 1 | 2017 | 102 | 0.120 |
Why?
|
| Lactic Acid | 2 | 2010 | 75 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 372 | 0.120 |
Why?
|
| Puerto Rico | 4 | 2020 | 141 | 0.120 |
Why?
|
| Placebos | 2 | 2008 | 73 | 0.120 |
Why?
|
| Diabetic Angiopathies | 1 | 2016 | 29 | 0.120 |
Why?
|
| Caloric Restriction | 2 | 2005 | 21 | 0.110 |
Why?
|
| Health Education | 2 | 2014 | 190 | 0.110 |
Why?
|
| Data Collection | 1 | 2017 | 384 | 0.110 |
Why?
|
| Prospective Studies | 7 | 2020 | 3329 | 0.110 |
Why?
|
| Health Promotion | 2 | 2017 | 523 | 0.110 |
Why?
|
| Aged | 4 | 2020 | 15089 | 0.110 |
Why?
|
| Sex Factors | 3 | 2008 | 995 | 0.110 |
Why?
|
| Analysis of Variance | 3 | 2010 | 606 | 0.100 |
Why?
|
| Kinetics | 2 | 2007 | 757 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2016 | 322 | 0.100 |
Why?
|
| Anxiety | 2 | 2020 | 427 | 0.100 |
Why?
|
| Blood Chemical Analysis | 1 | 2013 | 20 | 0.100 |
Why?
|
| Anthropometry | 1 | 2013 | 86 | 0.100 |
Why?
|
| Foot | 1 | 2013 | 42 | 0.100 |
Why?
|
| Resistance Training | 1 | 2013 | 22 | 0.090 |
Why?
|
| Cholesterol, HDL | 1 | 2013 | 71 | 0.090 |
Why?
|
| Algorithms | 2 | 2008 | 1052 | 0.090 |
Why?
|
| Epinephrine | 2 | 2002 | 46 | 0.090 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 294 | 0.090 |
Why?
|
| Animals | 4 | 2019 | 21459 | 0.090 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 279 | 0.080 |
Why?
|
| Triglycerides | 1 | 2013 | 248 | 0.080 |
Why?
|
| Hypertension | 1 | 2016 | 616 | 0.080 |
Why?
|
| Affect | 1 | 2011 | 131 | 0.080 |
Why?
|
| Self Efficacy | 1 | 2011 | 206 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2013 | 535 | 0.080 |
Why?
|
| Treatment Outcome | 1 | 2020 | 5820 | 0.070 |
Why?
|
| Menstrual Cycle | 3 | 2006 | 83 | 0.070 |
Why?
|
| Blotting, Western | 1 | 2010 | 611 | 0.070 |
Why?
|
| Dietary Proteins | 1 | 2008 | 44 | 0.070 |
Why?
|
| Thyroid Hormones | 1 | 2008 | 81 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2023 | 1026 | 0.070 |
Why?
|
| Electron Transport Complex I | 1 | 2008 | 15 | 0.070 |
Why?
|
| Glycerol | 1 | 2007 | 34 | 0.070 |
Why?
|
| Muscle Proteins | 1 | 2008 | 117 | 0.070 |
Why?
|
| Dietary Fats | 1 | 2008 | 181 | 0.060 |
Why?
|
| Catecholamines | 2 | 2006 | 31 | 0.060 |
Why?
|
| Hypoxia | 1 | 2008 | 121 | 0.060 |
Why?
|
| Phosphorylation | 1 | 2010 | 963 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 1172 | 0.060 |
Why?
|
| Anterior Cruciate Ligament | 1 | 2006 | 22 | 0.060 |
Why?
|
| Depression | 1 | 2013 | 908 | 0.060 |
Why?
|
| Physical Endurance | 1 | 2006 | 48 | 0.060 |
Why?
|
| Physical Exertion | 1 | 2006 | 81 | 0.060 |
Why?
|
| Anterior Cruciate Ligament Injuries | 1 | 2006 | 34 | 0.060 |
Why?
|
| Hyperphagia | 1 | 2006 | 18 | 0.060 |
Why?
|
| Joint Instability | 1 | 2006 | 57 | 0.060 |
Why?
|
| Athletic Injuries | 1 | 2006 | 82 | 0.060 |
Why?
|
| Metabolic Clearance Rate | 1 | 2005 | 48 | 0.060 |
Why?
|
| Hormone Antagonists | 1 | 2005 | 12 | 0.060 |
Why?
|
| Lipid Peroxidation | 1 | 2005 | 67 | 0.060 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2005 | 88 | 0.060 |
Why?
|
| Osteoarthritis, Knee | 1 | 2010 | 401 | 0.050 |
Why?
|
| Research Design | 1 | 2008 | 590 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2006 | 323 | 0.050 |
Why?
|
| Dominican Republic | 2 | 2014 | 23 | 0.050 |
Why?
|
| Antioxidants | 1 | 2006 | 252 | 0.050 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2003 | 15 | 0.050 |
Why?
|
| Surveys and Questionnaires | 4 | 2015 | 2789 | 0.050 |
Why?
|
| Knee Joint | 1 | 2006 | 312 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 805 | 0.050 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2003 | 80 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 604 | 0.050 |
Why?
|
| Hand Strength | 1 | 2023 | 34 | 0.050 |
Why?
|
| Motivation | 2 | 2015 | 298 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2002 | 106 | 0.050 |
Why?
|
| Logistic Models | 2 | 2017 | 1273 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 708 | 0.040 |
Why?
|
| Models, Animal | 1 | 2002 | 242 | 0.040 |
Why?
|
| Muscles | 1 | 2002 | 179 | 0.040 |
Why?
|
| United States | 3 | 2014 | 8166 | 0.040 |
Why?
|
| Pulse Wave Analysis | 1 | 2020 | 15 | 0.040 |
Why?
|
| Brachial Artery | 1 | 2020 | 27 | 0.040 |
Why?
|
| Sports Medicine | 2 | 2010 | 28 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2002 | 200 | 0.040 |
Why?
|
| Ecological Momentary Assessment | 1 | 2020 | 8 | 0.040 |
Why?
|
| Proteins | 1 | 2005 | 764 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2002 | 301 | 0.040 |
Why?
|
| Athletes | 1 | 2020 | 109 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 462 | 0.040 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2019 | 206 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2011 | 593 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2019 | 624 | 0.030 |
Why?
|
| Gestational Age | 1 | 2018 | 194 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2017 | 2639 | 0.030 |
Why?
|
| Incidence | 2 | 2014 | 1432 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 757 | 0.030 |
Why?
|
| Counseling | 2 | 2009 | 376 | 0.030 |
Why?
|
| Pre-Eclampsia | 1 | 2016 | 72 | 0.030 |
Why?
|
| Rats | 1 | 2019 | 1996 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2015 | 47 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 448 | 0.030 |
Why?
|
| Patient Education as Topic | 2 | 2009 | 489 | 0.030 |
Why?
|
| Weight Reduction Programs | 1 | 2015 | 63 | 0.030 |
Why?
|
| Goals | 1 | 2014 | 96 | 0.030 |
Why?
|
| Pregnancy Trimester, First | 1 | 2013 | 24 | 0.030 |
Why?
|
| Strikes, Employee | 1 | 2013 | 3 | 0.020 |
Why?
|
| Shoes | 1 | 2013 | 13 | 0.020 |
Why?
|
| Poverty | 1 | 2015 | 307 | 0.020 |
Why?
|
| Carbohydrates | 1 | 2013 | 40 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 931 | 0.020 |
Why?
|
| Maternal Welfare | 1 | 2011 | 15 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 2326 | 0.020 |
Why?
|
| Oxygen | 1 | 2013 | 321 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2013 | 535 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 413 | 0.020 |
Why?
|
| Health Surveys | 1 | 2011 | 319 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2011 | 274 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 498 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2013 | 475 | 0.020 |
Why?
|
| Self Report | 1 | 2011 | 394 | 0.020 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2009 | 62 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2010 | 295 | 0.020 |
Why?
|
| Women's Health | 1 | 2011 | 376 | 0.020 |
Why?
|
| Educational Status | 1 | 2009 | 279 | 0.020 |
Why?
|
| Perception | 1 | 2008 | 186 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2010 | 1144 | 0.020 |
Why?
|
| Pain | 1 | 2009 | 400 | 0.010 |
Why?
|
| Self Care | 1 | 2008 | 218 | 0.010 |
Why?
|
| Range of Motion, Articular | 1 | 2006 | 116 | 0.010 |
Why?
|
| Diet, Reducing | 1 | 2005 | 25 | 0.010 |
Why?
|
| Carbon Isotopes | 1 | 2005 | 17 | 0.010 |
Why?
|
| Nitrogen | 1 | 2005 | 21 | 0.010 |
Why?
|
| Calorimetry | 1 | 2005 | 37 | 0.010 |
Why?
|
| Leucine | 1 | 2005 | 65 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2011 | 2113 | 0.010 |
Why?
|
| Plasma Volume | 1 | 2003 | 4 | 0.010 |
Why?
|
| Prazosin | 1 | 2003 | 7 | 0.010 |
Why?
|
| Phenylephrine | 1 | 2003 | 18 | 0.010 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2003 | 21 | 0.010 |
Why?
|
| Acclimatization | 1 | 2003 | 11 | 0.010 |
Why?
|
| Basal Metabolism | 1 | 2003 | 23 | 0.010 |
Why?
|
| Sympathetic Nervous System | 1 | 2003 | 35 | 0.010 |
Why?
|
| Estradiol | 1 | 2003 | 260 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 2730 | 0.010 |
Why?
|